CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00763139
NCT00763139N/ACompleted
CompareCT.gov

Inflammation and Insulin Resistance in Rheumatoid Arthritis

Vanderbilt University·interventional·Posted Sep 30, 2008·Updated Nov 13, 2014

In Brief

A clinical study evaluating Pioglitazone and Placebo for Rheumatoid Arthritis. Completed, enrolled 34 participants across 1 site.

Detailed Summary

Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness, and loss of function in the joints. Over time, joint deformity, joint destruction, and loss of function can occur. Current treatment aims to improve symptoms, but there is no cure for the disease. Pioglitazone is drug that is effective in treating people with diabetes. This study will determine whether pioglitazone can also be used to effectively treat people with RA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2008
Enrollment StartApr 1, 2009
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 17.8 years ago

Interventions

Pioglitazonedrug

45 mg by mouth once a day for 8 weeks

Placebodrug

By mouth once a day for 8 weeks